What is Pulmocide?
Pulmocide is a specialized biopharmaceutical company dedicated to addressing the significant unmet medical needs in the treatment of acute and chronic respiratory tract infections. These infections often lead to severe complications and profoundly impact patients' quality of life. The company's mission centers on developing novel therapeutic solutions to combat these debilitating conditions, positioning it as a key player in the respiratory health sector. Its strategic funding rounds indicate a strong investor confidence in its scientific approach and therapeutic pipeline.
How much funding has Pulmocide raised?
Pulmocide has raised a total of $149.9M across 3 funding rounds:
Series A
$27.5M
Series B
$30.4M
Series C
$92M
Series A (2013): $27.5M with participation from Johnson & Johnson Development Corporation, S.V. Life Sciences, F-Prime Capital, and Imperial Innovations Group plc
Series B (2017): $30.4M led by S.R. One, Longwood Fund, S.V. Life Sciences, F-Prime Capital, JJDC, Inc, and Touchstone Innovations plc
Series C (2021): $92M supported by Adjuvant Capital, SV Health Investors, Jeito Capital, Asahi Kasei Pharma, and SR One
Key Investors in Pulmocide
Adjuvant Capital
Adjuvant Capital is an investment firm that likely focuses on advancing health technologies and solutions, given its participation in Pulmocide's Series C funding.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, providing strategic and operational support.
What's next for Pulmocide?
With substantial enterprise-level backing and a recent strategic investment, Pulmocide is poised for accelerated growth and the advancement of its product pipeline. The company's trajectory suggests a focus on scaling operations, progressing through clinical trials, and potentially preparing for commercialization. The consistent flow of capital, particularly the recent major strategic investment, signals a critical phase for the company, likely involving significant R&D expansion and market penetration efforts in the competitive biopharmaceutical landscape.
See full Pulmocide company page
